Hexavalent vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hexavalent vaccine" in English language version.

refsWebsite

Global rank English rank

15web.archive.org

1^st place

10europa.eu

68^th place

117^th place

6nih.gov

4^th place

3doi.org

2^nd place

2tga.gov.au

3,984^th place

2,622^nd place

2semanticscholar.org

11^th place

8^th place

1ox.ac.uk

613^th place

456^th place

1drugs.com

399^th place

333^rd place

1fda.gov

447^th place

338^th place

1cdc.gov

218^th place

212^th place

1worldcat.org

5^th place

cdc.gov

Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.

doi.org

Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F (August 2018). "New perspectives for hexavalent vaccines". Vaccine. 36 (36): 5485–5494. doi:10.1016/j.vaccine.2017.06.063. PMID 28676382. S2CID 4384043.
Syed YY (February 2017). "DTaP5-HB-IPV-Hib Vaccine (Vaxelis): A Review of its Use in Primary and Booster Vaccination". Paediatr Drugs. 19 (1): 69–80. doi:10.1007/s40272-016-0208-y. PMID 28035545. S2CID 25164446.
Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.

drugs.com

"Vaxelis Approval History". Drugs.com. 30 December 2018. Archived from the original on 17 October 2019. Retrieved 16 October 2019.

europa.eu

ema.europa.eu

"Hexavac EPAR". European Medicines Agency (EMA). 16 August 2012. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Hexyon EPAR". European Medicines Agency (EMA). 12 July 2013. Archived from the original on 25 June 2019. Retrieved 28 June 2018.
"Vaxelis EPAR". European Medicines Agency (EMA). 19 February 2019. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Hexacima EPAR". European Medicines Agency (EMA). 12 July 2013. Archived from the original on 11 November 2020. Retrieved 30 September 2020.
"Infanrix Hexa EPAR". European Medicines Agency (EMA). 27 March 2019. Archived from the original on 25 June 2019. Retrieved 16 October 2019.
"Hexaxim H-W-2495". European Medicines Agency (EMA). Archived from the original on 2 October 2018. Retrieved 28 June 2018.
"European Medicines Agency recommends suspension of Hexavac". European Medicines Agency (EMA) (Press release). 20 September 2005. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Public statement on Hexavac [diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted] Withdrawal of marketing authorisation in the European Union" (PDF). European Medicines Agency (EMA). 24 July 2012. Archived (PDF) from the original on 21 December 2021. Retrieved 30 September 2022.
"European Medicines Agency gives first opinion for a vaccine for use outside the EU". European Medicines Agency (EMA) (Press release). 22 June 2012. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
European Medicines Agency (14 June 2016). "Hexaxim: Opinion on medicine for use outside EU". European Medicines Agency. Archived from the original on 3 August 2022. Retrieved 30 September 2022.

fda.gov

"Vaxelis". U.S. Food and Drug Administration (FDA). 17 October 2019. STN 125563. Archived from the original on 17 October 2019. Retrieved 16 October 2019. This article incorporates text from this source, which is in the public domain.

nih.gov

pubmed.ncbi.nlm.nih.gov

Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, et al. (June 2018). "Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts". Journal of Preventive Medicine and Hygiene. 59 (2): E107 – E119. PMC 6069402. PMID 30083617.
Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F (August 2018). "New perspectives for hexavalent vaccines". Vaccine. 36 (36): 5485–5494. doi:10.1016/j.vaccine.2017.06.063. PMID 28676382. S2CID 4384043.
Syed YY (February 2017). "DTaP5-HB-IPV-Hib Vaccine (Vaxelis): A Review of its Use in Primary and Booster Vaccination". Paediatr Drugs. 19 (1): 69–80. doi:10.1007/s40272-016-0208-y. PMID 28035545. S2CID 25164446.
Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.

ncbi.nlm.nih.gov

Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, et al. (June 2018). "Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts". Journal of Preventive Medicine and Hygiene. 59 (2): E107 – E119. PMC 6069402. PMID 30083617.
Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.

ox.ac.uk

vk.ovg.ox.ac.uk

"6-in-1 Vaccine". Vaccine Knowledge Group. 29 June 2018. Archived from the original on 3 July 2018. Retrieved 3 July 2018.

semanticscholar.org

api.semanticscholar.org

Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F (August 2018). "New perspectives for hexavalent vaccines". Vaccine. 36 (36): 5485–5494. doi:10.1016/j.vaccine.2017.06.063. PMID 28676382. S2CID 4384043.
Syed YY (February 2017). "DTaP5-HB-IPV-Hib Vaccine (Vaxelis): A Review of its Use in Primary and Booster Vaccination". Paediatr Drugs. 19 (1): 69–80. doi:10.1007/s40272-016-0208-y. PMID 28035545. S2CID 25164446.

tga.gov.au

"Vaxelis APMDS". Therapeutic Goods Administration (TGA). 6 April 2022. Retrieved 24 April 2022.
"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

web.archive.org

"6-in-1 Vaccine". Vaccine Knowledge Group. 29 June 2018. Archived from the original on 3 July 2018. Retrieved 3 July 2018.
"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
"Hexavac EPAR". European Medicines Agency (EMA). 16 August 2012. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Hexyon EPAR". European Medicines Agency (EMA). 12 July 2013. Archived from the original on 25 June 2019. Retrieved 28 June 2018.
"Vaxelis EPAR". European Medicines Agency (EMA). 19 February 2019. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Hexacima EPAR". European Medicines Agency (EMA). 12 July 2013. Archived from the original on 11 November 2020. Retrieved 30 September 2020.
"Infanrix Hexa EPAR". European Medicines Agency (EMA). 27 March 2019. Archived from the original on 25 June 2019. Retrieved 16 October 2019.
"Vaxelis Approval History". Drugs.com. 30 December 2018. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Hexaxim H-W-2495". European Medicines Agency (EMA). Archived from the original on 2 October 2018. Retrieved 28 June 2018.
"European Medicines Agency recommends suspension of Hexavac". European Medicines Agency (EMA) (Press release). 20 September 2005. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Public statement on Hexavac [diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted] Withdrawal of marketing authorisation in the European Union" (PDF). European Medicines Agency (EMA). 24 July 2012. Archived (PDF) from the original on 21 December 2021. Retrieved 30 September 2022.
"European Medicines Agency gives first opinion for a vaccine for use outside the EU". European Medicines Agency (EMA) (Press release). 22 June 2012. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
European Medicines Agency (14 June 2016). "Hexaxim: Opinion on medicine for use outside EU". European Medicines Agency. Archived from the original on 3 August 2022. Retrieved 30 September 2022.
"Vaxelis". U.S. Food and Drug Administration (FDA). 17 October 2019. STN 125563. Archived from the original on 17 October 2019. Retrieved 16 October 2019. This article incorporates text from this source, which is in the public domain.
Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.

worldcat.org

search.worldcat.org

Oliver SE, Moore KL (6 February 2020). "Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5): 136–9. doi:10.15585/mmwr.mm6905a5. ISSN 0149-2195. PMC 7004397. PMID 32027629. Archived (PDF) from the original on 7 May 2020. Retrieved 30 September 2022. This article incorporates text from this source, which is in the public domain.